Trial Profile

A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Pasireotide LAR in Patients With Cushing's Disease

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 16 Jun 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

18 May 2022 Results from LINC-3, CSOM230G2304 and other study evaluating the relative time to complete response (CR) of osilodrostat compared with pasireotide subcutaneous (SC) and long-acting release (LAR) for patients with CD presented at the 27th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research
10 Jan 2022 New source identified and integrated (Japan Pharmaceutical Information Center - Clinical Trials Information record: JapicCTI111695).
08 May 2020 Results assessing whether, Long-acting pasireotide improves clinical signs and quality of life in Cushing's disease, published in the Journal of Endocrinological Investigation

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com